A 6-month aerobic exercise intervention significantly improved self-reported chemotherapy-induced peripheral neuropathy among women who underwent chemotherapy … Read more
The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.
The phase 1/2 UPLIFT trial (NCT03319628) … Read more
Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC
In Science Advances, Nagoya University scientists publish their work discovering three membrane proteins associated with ovarian cancer. The research team are hopeful that their discovery could improve approaches for detecting and diagnosing the disease.
Recently, a study from Imperial School of Public Health (SPH) has been in the news1. The findings suggest a link between higher consumption of ultra-processed foods and developing cancer. As with many articles about research, it’s important to … Read more
Three organizations have joined together to provide oncologists with recommendations for how to treat patients with gynecologic cancers in light of current chemotherapy shortages.
The recommendations, which pertain to the shortages of cisplatin, carboplatin, and methotrexate, were released by the … Read more
Key Points:
Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the … Read more
CHICAGO – Twice as many patients with folate receptor alpha (FRα)-positive, advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer responded to ImmunoGen’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) than did patients on chemotherapy in a confirmatory Phase III trial.… Read more
Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the … Read more
CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more
Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.
In an
Researchers examined risks for Black and white women with endometriosis and fibroids to understand how common medical interventions for those conditions modified the outcomes
SEATTLE, WA — May 4, 2023 — A new Fred Hutchinson Cancer Center study in the
by Jordan Sava
Impressive efficacy data and consistent safety data continue to be seen with mirvetuximab soravtansine for the treatment of patients with platinum-resistant ovarian cancer, according to data from the confirmatory MIRASOL trial.
Mirvetuximab sorvtansine-gynx (Elahere) demonstrated statistically significant
Clearity’s Perspective: Ask your health care team if they have a social worker, financial navigator, patient navigator, or nurse navigator who can help you manage the financial impacts of cancer. See Clearity’s Information and Support Resources for national organizations that … Read more
by Jennifer Southall
Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.
The findings, presented at American Association … Read more
by Leah Lawrence
Early-phase trials testing the safety and efficacy of PARP inhibition plus ataxia telangiectasia- and Rad3-related kinase (ATR) inhibition in biomarker-selected patients show intriguing results, researchers reported at the AACR Annual Meeting 2023.
“ATR inhibition prevents recovery from … Read more
There are currently three antibody drug conjugates (ADC) targeting B7-H4 being tested in clinical trials: AZD8205 (NCT05123482), SGN-B7-H4V (NCT05194072) and XMT-1660 (NCT05377996). You can use Clearity’s clinical trial finder to find more information about these trials.
As part of the … Read more
Reviewed by Emily Henderson, B.Sc
Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare … Read more
by Nichole Tucker
The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.
The investigational combination of lifirafenib (BGB-283) and mirdametinib (PD-0325901) has shown a favorable safety profile, as well … Read more
